利多卡因与胺碘酮用于儿童院内心脏骤停:一项观察性研究
该研究基于Get With The Guidelines - Resuscitation登记数据库,纳入2000至2018年≤18岁院内心脏骤停且初始或后续出现可电击心律(心室颤动和无脉性室性心动过速)的患儿,比较利多卡因与胺碘酮的临床结局。共365例患者纳入分析,其中180例(49%)经倾向性评分匹配。匹配队列中,利多卡因组与胺碘酮组在自主循环恢复(RR 0.99,95%CI 0.82-1.19;p=0.88)、24小时生存(RR 1.02,95%CI 0.76-1.38;p=0.88)、出院生存(RR 1.01,95%CI 0.63-1.63;p=0.96)及良好神经预后(RR 0.65,95%CI 0.35-1.21;p=0.17)方面均无统计学显著差异,多种敏感性分析结果一致。
要点
- 在匹配队列中,利多卡因与胺碘酮相比,自主循环恢复无统计学显著差异(RR 0.99,95%CI 0.82-1.19;p=0.88)。
- 24小时生存率在利多卡因组与胺碘酮组间无统计学显著差异(RR 1.02,95%CI 0.76-1.38;p=0.88)。
- 出院生存率在两组间无统计学显著差异(RR 1.01,95%CI 0.63-1.63;p=0.96)。
- 良好神经预后在两组间无统计学显著差异(RR 0.65,95%CI 0.35-1.21;p=0.17)。
- 多种敏感性分析结果与主要分析一致。
适用人群与场景
- ≤18岁院内心脏骤停患者,初始或后续出现可电击心律(心室颤动和无脉性室性心动过速),来自Get With The Guidelines - Resuscitation登记数据库,2000至2018年。
研究设计与关键结果
- 研究类型为观察性队列研究(基于Get With The Guidelines - Resuscitation登记数据库),共365例患者纳入分析,其中180例(49%)经倾向性评分匹配。
- 原始队列中位年龄6岁(四分位数0.5-14岁),164例(45%)为女性,238例(65%)因初始可电击心律接受抗心律失常药物。
- 匹配队列中,利多卡因组与胺碘酮组自主循环恢复无统计学显著差异(RR 0.99,95%CI 0.82-1.19;p=0.88)。
- 匹配队列中,利多卡因组与胺碘酮组24小时生存无统计学显著差异(RR 1.02,95%CI 0.76-1.38;p=0.88)。
- 匹配队列中,利多卡因组与胺碘酮组出院生存无统计学显著差异(RR 1.01,95%CI 0.63-1.63;p=0.96)。
- 匹配队列中,利多卡因组与胺碘酮组良好神经预后无统计学显著差异(RR 0.65,95%CI 0.35-1.21;p=0.17)。
- 多种敏感性分析结果与主要分析一致。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在因可电击心律接受抗心律失常药物治疗的儿童心脏骤停患者中,利多卡因与胺碘酮相比临床结局无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Lidocaine and amiodarone are both included in the pediatric cardiac arrest guidelines as treatments of shock-refractory ventricular fibrillation or pulseless ventricular tachycardia, although there is limited evidence to support this recommendation.
METHODS: In this cohort study from the Get With The Guidelines - Resuscitation registry, we included pediatric patients (≤18 years) with an in-hospital cardiac arrest between 2000 and 2018, who presented with an initial or subsequent shockable rhythm (ventricular fibrillation and pulseless ventricular tachycardia). Patients receiving amiodarone were matched to patients receiving lidocaine based on a propensity score, calculated from multiple patient, event, and hospital characteristics.
RESULTS: A total of 365 patients were available for the analysis, of which 180 (49%) patients were matched on the propensity score. The median age in the raw cohort was 6 (quartiles, 0.5-14) years, 164 (45%) patients were female, and 238 (65%) patients received an antiarrhythmic for an initial shockable rhythm. In the matched cohort, there were no statistically significant differences between patients receiving lidocaine compared to amiodarone in return of spontaneous circulation (RR, 0.99 [95%CI, 0.82-1.19]; p = 0.88), survival to 24 h (RR, 1.02 [95%CI, 0.76-1.38]; p = 0.88), survival to hospital discharge (RR, 1.01 [95%CI, 0.63-1.63]; p = 0.96), and favorable neurological outcome (RR, 0.65 [95%CI, 0.35-1.21]; p = 0.17). The results remained consistent in multiple sensitivity analyses.
CONCLUSIONS: In children with cardiac arrest receiving antiarrhythmics for a shockable rhythm, there was no significant difference in clinical outcomes between those receiving lidocaine compared to amiodarone.
参考来源
- Holmberg MJ, Ross CE, Atkins DL, et al. Lidocaine versus amiodarone for pediatric in-hospital cardiac arrest: An observational study. Resuscitation. 2020. PMID: 31954741. doi:10.1016/j.resuscitation.2019.12.033
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。